Genetic Prostate Cancer Studies Are Needed to Push the Needle Forward

Commentary
Video

Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.

Research into genetic testing as a tool for localized diagnosis is still in its early days across most cancer types, and prostate cancer is no exception, according to William J. Catalona, MD.

In a conversation with CancerNetwork® during the 2023 Society of Urologic Oncology (SUO) Annual Meeting, Catalona, a professor of urology at the Feinberg School of Medicine, Northwestern University, emphasized the necessity of conducting additional genetic studies in the prostate cancer space to collect firm evidence. From there, robust guidelines can be drafted and implemented.

Transcript:

We're relatively early in the phase of genetic studies of prostate cancer. Many of [our] colleagues may not be as familiar with all of the latest developments if their area is focused in, say, radiation therapy, medical oncology, or other areas. Hopefully, they [have] learned a little something about what's current in the genetics of prostate cancer [from my presentation]. The other thing is that we really need to [base] our clinical guidelines for managing patients on firm scientific evidence. Without the genetic research, that firm scientific evidence is not there. Once we have the firm scientific evidence, then we have robust guidelines. But then we have to move beyond the robust guidelines into a field called implementation science, where we have to persuade the doctors and patients out there to do the right thing because there's good scientific evidence to support adopting these guidelines.

Reference

Catalona WJ. Localized diagnosis: genetic testing. 2023 Society of Urologic Oncology (SUO) Annual Meeting; November 28-December 1, 2023; Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Related Content